Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

Furthers Mission to Address Unmet Therapeutic and Wellness Needs Across the Globe

TAMPA, Florida, Sept. 4, 2018 /PRNewswire/ -- Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No. 2 902 452 ("the '452 patent"). The '452 patent has broad claims to biosynthetic methods for the production of cannabinoids, cannabinoid prodrugs and cannabinoid analogs.

Dr. Richard Peet, Teewinot's Executive Vice President, stated that "with the grant of the '452' patent, Teewinot is well positioned to compete in the important Canadian nutraceutical and pharmaceutical markets. Teewinot is the only company capable of producing large quantities of naturally-occurring cannabinoids that are only produced in the plant in small quantities such as CBCA and varin series of cannabinoids. The '452 patent is the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology. Teewinot has a large portfolio patents in the U.S., and in key countries around the world, with claims covering biosynthetic production of cannabinoids. These biosynthetic processes provide Teewinot with the capability of cost-effectively producing 18 naturally-occurring cannabinoids in pharmaceutically pure form and in large quantities, without having to cultivate the Cannabis plant."

Charlie Brink, Teewinot's Chairman, stated "we are happy to announce the issuance of the '452' patent as it's the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology. Teewinot has demonstrated that these proprietary equipment and methods improve a wide range of production metrics, and we look forward to partnering with customers that could benefit from these advantages in the global marketplace."

Teewinot is currently in the process of identifying leading commercial consumer products partnerships in this space that will allow the cannabinoid market to benefit from our rapidly expanding technology platforms in the areas of biocatalytic production of cannabinoids, cannabinoid prodrugs and analogs. With Teewinot's unique ability to cost-effectively manufacture industrial quantities of exact cannabinoid molecules and modify delivery methods may become an indispensable asset in the global quest to develop new, effective cannabinoid therapeutics. The company's system diversifies the number and types of molecules that can be made available for research, product development, commercial products and pharmaceutical production of potentially life changing drugs.

About Teewinot Life Sciences Corporation

Teewinot Life Sciences, an international cannabinoid biotechnology company, has set out to revolutionize the cannabis market by becoming the leader in the use of patented biocatalytic and plant-based technologies that make the full spectrum of cannabinoids available in industrial quantities, in order to address therapeutic and wellness needs across all consumer sectors. With headquarters in Tampa Florida and subsidiaries Teewinot Technologies, Ltd. in Ireland and Teewinot Laboratories, Inc. in Canada, The Teewinot Group's revolutionary technologies and intellectual property portfolio represent a breakthrough in creating safe and standardized cannabinoids.

For More Information:

Teewinot Life Sciences Corporation
Kelly Coughlin ? Public Relations
[email protected]
(954) 294-9135

Eric A. Walker ? CIO
[email protected]
(813) 607-2909

Logo - https://mma.prnewswire.com/media/480150/Teewinot_Life_Sciences_Logo.jpg